NOTE! 1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice. 2. Do NOT open position WITHOUT chart confirmation, indicators, momentum. 3. Scale out and secure profits. 4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability. 5. I DO NOT give buy or sell advice 6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow) 7. NEVER be a blind follower. LASTLY, ...
IamBadNewz
:
@Jaguar8 Been waiting (im)patiently for a pop on CGTX given the recent conference and news of insider buying but price hasn’t reacted. Your thoughts?
Here have some gifts, my weekend work so far: $Yalla (YALA.US)$diversity outside Asia/us, expanding reach $NexGel (NXGL.US)$specialized medical applications will see higher demand as the saline shortage goes on, and more look to alternatives $Lumen Technologies (LUMN.US)$ongoing transitions, personally see an increase in presence (which is impressive, honestly, I'm a nobody in random town), and they are approaching good buy levels $Rezolute (RZLT.US)$also approaching oversold $Ventyx Biosciences (VTYX.US)$impressiv...
4
1
Report
Tonyco
OP
:
(all of them tank 30%, is murdered under mysterious circumstances days later)
$Ventyx Biosciences (VTYX.US)$ Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024 Ventyx Biosciences (Nasdaq: VTYX) presented new 52-week results from the Phase 2 trial of VTX002 (tamuzimod) in ulcerative colitis at UEG Week 2024. The late-breaking abstract highlighted high rates of clinical and endoscopic remission among long-term extension (LTE) completers at Week 52. CEO Raju Mohan emphasized the data's reinfo...
$Ventyx Biosciences (VTYX.US)$ Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price...
$Ventyx Biosciences (VTYX.US)$ Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease Ventyx Biosciences (Nasdaq: VTYX) has initiated dosing in a Phase 2a trial of VTX3232 for early Parkinson's disease. The trial aims to evaluate the drug's effects on disease- and target-relevant biomarkers, including exploratory PET neuroimaging to measure its impact on microglial activation. This study is based on evidence suggesting a str...
1
Report
No comment yet
Sign in to post a comment
Trending Stocks
Top Gaining Chinese Stocks Top Gaining Chinese Stocks
kingrotch : thank you for your work![pray 🙏](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f64f-1f3fb.png)
![pray 🙏](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f64f-1f3fb.png)
![pray 🙏](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f64f-1f3fb.png)
真名有晨 : Thank you very much
Please take care and rest.
iluvpoptarts : sry doc. I'm too busy counting the money your making me too look. muha
IamBadNewz : @Jaguar8 Been waiting (im)patiently for a pop on CGTX given the recent conference and news of insider buying but price hasn’t reacted. Your thoughts?
Jaguar8 OP IamBadNewz : You have to be patient
View more comments...